All In Biotech

Drug Trial Radar · NCT05035030

Long-term Safety and Efficacy of Odevixibat in Patients With Alagille Syndrome

An Open Label Study to Evaluate the Long-term Safety and Efficacy of Odevixibat (A4250) in Patients With Alagille Syndrome (ASSERT-EXT)

Last checked: Nov 20, 2026Latest source record: Oct 23, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

62

Actual

Start

Sep 3, 2021

Primary completion

Feb 15, 2027

Study completion Feb 15, 2027

Sponsor

Lead sponsor
Albireo, an Ipsen CompanyIndustry
Sponsor type
Industry
First posted
Sep 5, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to assess the long-term safety and effectiveness of odevixibat in participants with Alagille syndrome (ALGS). The participants of this study will have ALGS a rare genetic disorder that can affect multiple organ systems of the body including the liver, heart, skeleton, eyes and kidneys. Common symptoms, which often develop during the first three months of life, include blockage of the flow of bile from the liver (cholestasis), yellowing of the skin and mucous membranes (jaundice), poor weight gain and growth and severe itching (pruritis). The drug used for the study is odevixibat and was authorized for the treatment of cholestatic pruritus in infants with ALGS over 12 months of age by the United States Food and Drug Administration on 13 June 2023.

Conditions

  • Alagille Syndrome

Interventions

  • OdevixibatDrug

    Odevixibat is a small molecule and selective inhibitor of IBAT.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change from baseline in pruritusTime frame: Baseline to week 72 (cohort 1).
  2. Percentage of participants with Treatment Emergent Adverse Event (TEAEs) and Serious Adverse Events (SAEs)Time frame: Baseline to week 12 (cohort 2).
  3. Percentage of participants with clinically significant changes from baseline in Physical ExaminationTime frame: Baseline to week 12 (cohort 2).
  4. Percentage of participants with clinically significant changes in Laboratory ParametersTime frame: Baseline to week 12 (cohort 2).
  5. Percentage of participants with clinically significant changes from baseline in Vital Signs.Time frame: Baseline to week 12 (cohort 2).
  6. Change from baseline in concomitant medications.Time frame: Baseline to week 12 (cohort 2).
  7. Change from baseline in fat-soluble vitamin levels.Time frame: Baseline to week 12 (cohort 2).

Locations

35 sites in 10 countries. Site status is shown where the registry gives one.

  • Rady Children's Hospital

    San Diego, California

  • UCSF

    San Francisco, California

  • Children's Healthcare of Atlanta

    Atlanta, Georgia

  • Riley Hospital for Children at IU Health

    Indianapolis, Indiana

  • Johns Hopkins Hospital

    Baltimore, Maryland

  • Boston Children's Hospital

    Boston, Massachusetts

  • Children's Mercy Hospital and Clinics

    Kansas City, Missouri

  • Northwell Health System

    New Hyde Park, New York

  • Hassenfeld Children's Hospital at NYU Langone

    New York, New York

  • New York-Presbyterian / Columbia University Irving Medical Center

    New York, New York

  • The Childrens Hospital at Montefiore Albert Einstein School of Medicine

    The Bronx, New York

  • Atrium Health Carolinas Medical

    Durham, North Carolina

  • Cincinnati Children's Hospital

    Cincinnati, Ohio

  • Oregon Health Science University School of Medicine

    Portland, Oregon

  • Monroe Carell Jr. Childrens Hospital at Vanderbilt

    Nashville, Tennessee

  • Childrens Medical Center of Dallas University of Texas Southwestern

    Dallas, Texas

  • Texas Children's Hospital

    Houston, Texas

  • Texas Liver Institute

    San Antonio, Texas

  • Cliniques Universitaires Saint-Luc Bruxelles

    Brussels, Belgium

  • Hôpital Femme Mère Enfant de Lyon

    Bron, France

  • Antenne pediatrique du CIC-Hopital Jeanne De Flandre

    Lille, France

  • Hopital Necker Enfants Malades

    Paris, France

  • Charité - Universitätsmedizin Berlin

    Berlin, Germany

  • Medizinische Hochschul

    Hanover, Germany

  • Universitatsklinik fur Kinder-und Jugendmedizin Tubingen

    Tübingen, Germany

  • AOU Meyer

    Florence, Italy

  • Azienda Ospedale University

    Padova, Italy

  • Ospedale Pediatrico Bambino Gesu

    Rome, Italy

  • University of Malaya Medical Center

    Kuala Lumpur, Malaysia

  • Universitair Medisch Centrum Groningen

    Groningen, Netherlands

  • Wilhelmina Children's Hospital UMCU Utrecht

    Utrecht, Netherlands

  • Instytut Pomnik-Centrum Zdrowia Dzieck

    Warsaw, Poland

  • Istanbul University Istanbul Medical Faculty Hospital

    Istanbul, Turkey (Türkiye)

  • Birmingham Women's and Children's NHS Foundation Trust

    Birmingham, United Kingdom

  • King's College Hospital NHS Foundation Trust King's College Hospital Paediatric Research

    London, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.